Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Receives Average Recommendation of “Reduce” from Brokerages

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) has earned an average recommendation of “Reduce” from the eleven research firms that are covering the stock, MarketBeat Ratings reports. Five research analysts have rated the stock with a sell rating and six have given a hold rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $23.5667.

A number of equities research analysts have issued reports on FMS shares. Truist Financial set a $25.00 price objective on shares of Fresenius Medical Care AG & Co. KGaA in a report on Wednesday, August 5th. Weiss Ratings reissued a “hold (c)” rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Tuesday, August 4th. Sanford C. Bernstein upped their target price on shares of Fresenius Medical Care AG & Co. KGaA from $25.50 to $25.80 and gave the stock a “market perform” rating in a research report on Thursday, August 6th. Jefferies Financial Group raised shares of Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “moderate sell” rating in a research note on Friday, May 8th. Finally, Citigroup reiterated a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Friday, July 17th.

Institutional Investors Weigh In On Fresenius Medical Care AG & Co. KGaA

A number of hedge funds have recently made changes to their positions in the company. Brooklyn Investment Group raised its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 5.4% during the 4th quarter. Brooklyn Investment Group now owns 8,860 shares of the company’s stock worth $212,000 after acquiring an additional 450 shares in the last quarter. Advisors Preferred LLC grew its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 6.1% in the first quarter. Advisors Preferred LLC now owns 10,226 shares of the company’s stock valued at $231,000 after purchasing an additional 589 shares in the last quarter. Hantz Financial Services Inc. grew its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 10.5% in the fourth quarter. Hantz Financial Services Inc. now owns 7,370 shares of the company’s stock valued at $176,000 after purchasing an additional 699 shares in the last quarter. Fifth Third Bancorp increased its position in Fresenius Medical Care AG & Co. KGaA by 4.0% in the fourth quarter. Fifth Third Bancorp now owns 18,766 shares of the company’s stock worth $447,000 after purchasing an additional 726 shares during the last quarter. Finally, Arax Advisory Partners increased its position in Fresenius Medical Care AG & Co. KGaA by 121.6% in the fourth quarter. Arax Advisory Partners now owns 1,613 shares of the company’s stock worth $38,000 after purchasing an additional 885 shares during the last quarter. 8.37% of the stock is currently owned by hedge funds and other institutional investors.

Fresenius Medical Care AG & Co. KGaA Trading Up 0.8%

Shares of Fresenius Medical Care AG & Co. KGaA stock opened at $22.66 on Monday. Fresenius Medical Care AG & Co. KGaA has a fifty-two week low of $20.02 and a fifty-two week high of $27.64. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 1.07. The company has a market capitalization of $12.17 billion, a P/E ratio of 11.74, a P/E/G ratio of 4.17 and a beta of 0.76. The company has a fifty day moving average of $23.86 and a 200 day moving average of $23.07.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last posted its quarterly earnings results on Monday, August 3rd. The company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.62 by $0.04. The business had revenue of $5.55 billion for the quarter, compared to analysts’ expectations of $5.48 billion. Fresenius Medical Care AG & Co. KGaA had a return on equity of 9.28% and a net margin of 4.83%. On average, sell-side analysts anticipate that Fresenius Medical Care AG & Co. KGaA will post 2.25 earnings per share for the current fiscal year.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.